{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T04:49:25Z","timestamp":1762490965255,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.lungcan.2025.108793","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:36:14Z","timestamp":1760027774000},"page":"108793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy and safety of brigatinib after alectinib in patients with ALK-positive NSCLC: Integrated analysis of the ALTA-2 and J-ALTA studies"],"prefix":"10.1016","volume":"209","author":[{"given":"Tony","family":"Mok","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4969-4165","authenticated-orcid":false,"given":"Makoto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentarou","family":"Kudou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1307-1505","authenticated-orcid":false,"given":"Takayuki","family":"Asato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3229-527X","authenticated-orcid":false,"given":"Xin","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pingkuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7342-0853","authenticated-orcid":false,"given":"Nobuyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7153","key":"10.1016\/j.lungcan.2025.108793_b0005","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.lungcan.2025.108793_b0010","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1158\/1078-0432.CCR-13-0318","article-title":"ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer","volume":"19","author":"Gainor","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.lungcan.2025.108793_b0015","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1158\/1078-0432.CCR-08-0168","article-title":"EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer","volume":"14","author":"Koivunen","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.lungcan.2025.108793_b0020","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.lungcan.2025.108793_b0025","unstructured":"Xalkori [package insert]. Pfizer Inc., New York, NY (2023)."},{"key":"10.1016\/j.lungcan.2025.108793_b0030","unstructured":"Zykadia [package insert]. Novartis Pharmaceuticals Corporation, East Hanover, NJ (2021)."},{"key":"10.1016\/j.lungcan.2025.108793_b0035","unstructured":"Alunbrig [package insert]. Takeda Pharmaceuticals America, Inc., Lexington, MA (2022)."},{"key":"10.1016\/j.lungcan.2025.108793_b0040","unstructured":"Alecensa [package insert]. Chugai Pharmaceutical Co., Ltd., Tokyo, Japan (2024)."},{"key":"10.1016\/j.lungcan.2025.108793_b0045","unstructured":"Lorbrena [package insert]. Pfizer Labs, New York, NY (2021)."},{"key":"10.1016\/j.lungcan.2025.108793_b0050","unstructured":"Ensacove [package insert]. Xcovery Holdings, Inc., Miami, FL (2024)."},{"issue":"23","key":"10.1016\/j.lungcan.2025.108793_b0055","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108793_b0060","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.lungcan.2025.108793_b0065","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non\u2013small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108793_b0070","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.lungcan.2025.108793_b0075","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108793_b0080","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial","volume":"7","author":"Horn","year":"2021","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108793_b0085","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.18632\/oncotarget.13741","article-title":"Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer","volume":"8","author":"Cui","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.lungcan.2025.108793_b0090","article-title":"Concordance between tissue ALK detection by immunohistochemistry and plasma ALK detection by next-generation sequencing in the randomized phase 3 ALEX study in patients with treatment-naive advanced ALK-positive NSCLC","volume":"3","author":"No\u00e9","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108793_b0095","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.jtho.2023.08.010","article-title":"Brigatinib versus alectinib in ALK-positive NSCLC after disease progression on crizotinib: results of phase 3 ALTA-3 trial","volume":"18","author":"Yang","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108793_b0100","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.lungcan.2021.06.012","article-title":"Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC","volume":"158","author":"Zhang","year":"2021","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2025.108793_b0105","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor\u2013naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108793_b0110","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jtho.2019.03.007","article-title":"Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study","volume":"14","author":"Camidge","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"28","key":"10.1016\/j.lungcan.2025.108793_b0115","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2015.65.8732","article-title":"Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer","volume":"34","author":"Yoshida","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108793_b0120","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1200\/JCO.2017.76.2294","article-title":"Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer","volume":"36","author":"Lin","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.lungcan.2025.108793_b0125","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-16-0569","article-title":"The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models","volume":"22","author":"Zhang","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108793_b0130","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1021\/acs.jmedchem.6b00306","article-title":"Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase","volume":"59","author":"Huang","year":"2016","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108793_b0135","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1111\/cas.15888","article-title":"Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: final results of the phase 2 J-ALTA trial","volume":"114","author":"Yoshida","year":"2023","journal-title":"Cancer Sci."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108793_b0140","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jtho.2022.08.018","article-title":"Efficacy of brigatinib in patients with advanced ALK-positive NSCLC who progressed on alectinib or ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)","volume":"17","author":"Ou","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"14","key":"10.1016\/j.lungcan.2025.108793_b0145","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2217\/fon-2020-1119","article-title":"ALTA-2: phase IIstudy of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib","volume":"17","author":"Kim","year":"2021","journal-title":"Future Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108793_b0150","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jtho.2020.11.004","article-title":"Brigatinib in Japanese patients with ALK-positive NSCLC previously treated with alectinib and other tyrosine kinase inhibitors: outcomes of the phase 2 J-ALTA trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108793_b0155","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol."},{"issue":"16","key":"10.1016\/j.lungcan.2025.108793_b0160","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.18.02236","article-title":"ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer","volume":"37","author":"Shaw","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108793_b0165","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.annonc.2021.02.012","article-title":"Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs","volume":"32","author":"Felip","year":"2021","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108793_b0170","article-title":"Long-term efficacy and safety of brigatinib in crizotinib-refractory ALK+ non\u2013small cell lung cancer: final results of the phase 1\/2 and randomized phase 2 (ALTA) trials","volume":"3","author":"Gettinger","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108793_b0175","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jtho.2024.11.021","article-title":"Final overall survival and long-term safety of lorlatinib in patients with ALK-positive NSCLC from the pivotal phase 2 study: a brief report","volume":"20","author":"Ou","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108793_b0180","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jtho.2018.11.022","article-title":"Interstitial lung disease onset and its risk factors in Japanese patients with ALK-positive NSCLC after treatment with crizotinib","volume":"14","author":"Gemma","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108793_b0185","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1111\/cas.12550","article-title":"Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10708 Japanese patients with non-small-cell lung cancer","volume":"105","author":"Gemma","year":"2014","journal-title":"Cancer Sci."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108793_b0190","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","article-title":"Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study","volume":"177","author":"Kudoh","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3 suppl 1","key":"10.1016\/j.lungcan.2025.108793_b0195","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/S1556-0864(25)00283-7","article-title":"Real-world occurrence of early-onset pulmonary events with brigatinib for advanced ALK+ NSCLC [abstract 88P]","volume":"20","author":"Hochmair","year":"2025","journal-title":"J. Thorac. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T04:45:47Z","timestamp":1762490747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225006853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":39,"alternative-id":["S0169500225006853"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108793","relation":{},"ISSN":["0169-5002"],"issn-type":[{"type":"print","value":"0169-5002"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of brigatinib after alectinib in patients with ALK-positive NSCLC: Integrated analysis of the ALTA-2 and J-ALTA studies","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108793","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Takeda Development Center Americas, Inc. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108793"}}